Andere talen Fennec Pharmaceuticals Inc.

Aandelen

FENC

CA31447P1009

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,57 ^USD	-1,34%		-11,63%	-14,71%

17/04	Insider bij Fennec Pharmaceuticals verkocht aandelen ter waarde van $457.182, volgens een recent SEC-document	MT
05/04	Insider bij Fennec Pharmaceuticals verkocht aandelen ter waarde van $958.669, volgens een recent SEC-document	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	17/04
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	05/04
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	03/04
Wedbush on Fennec's Q4	21/03
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	21/03
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	21/03
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	21/03
North American Morning Briefing : Investors -2-	21/03
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	21/03
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update	21/03
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024	19/03
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024	19/03
Wedbush on Fennec's Deal for Pedmarqsi in EU	18/03
Sector Update: Health Care Stocks Steady Premarket Monday	18/03
Sector Update: Health Care	18/03
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ	18/03
Fennec Pharmaceuticals Brief: Fennec Pharmaceuticals and Norgine Over the Weekend Entered into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	18/03
Fennec Pharmaceuticals Signs Exclusive Licensing Deal With Norgine	18/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Fennec Pharmaceuticals Inc.

Aandelen

FENC

CA31447P1009

Andere talen

Filters